COMMUNIQUÉS West-GlobeNewswire
-
Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia
29/05/2026 -
Seer Files ITC Complaint Against Nanomics
29/05/2026 -
Cannabix Expands BreathLogix Alcohol Screening Technology into Mining, Municipal and Aviation Sectors in Australia
29/05/2026 -
Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment
29/05/2026 -
Mud Wtr Reviews: Is This Mushroom Coffee Alternative Worth Drinking?
29/05/2026 -
The Next Great AI Revolution May Be Drug Delivery
29/05/2026 -
PICARD MEDICAL, INC. Issues Letter to Shareholders
29/05/2026 -
PetMed Express, Inc. to Report Fourth Quarter and Fiscal Year 2026 Financial Results on Tuesday, June 2, 2026
29/05/2026 -
EDAP Announces Corporate Name Change to FocalTherics™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy
29/05/2026 -
Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits
29/05/2026 -
SkyAI Appoints Veteran Finance Executive Arthur Levine as Chief Financial Officer
29/05/2026 -
Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026
29/05/2026 -
Imviva Biotech to Present Data from Clinical Studies of CTA313 and CTD402 Validating its ANSWER™ Allogeneic CAR-T Platform in Pediatric and Adult Patient Populations at EULAR and EHA 2026 Congresses
29/05/2026 -
Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical
29/05/2026 -
Spectral Medical Announces PMA Submission to U.S. FDA for PMX
29/05/2026 -
AEON Clinic Redefines Longevity with Premier NAD+ IV Therapy and Premium IV Drips in Dubai
29/05/2026 -
Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds
29/05/2026 -
Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026
29/05/2026 -
Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes
29/05/2026
Pages